How much does Firazyr (Icatibant Acetate Injection) Cost& price without insurance in China?
Firazyr® is the commercial brand name of Icatibant Acetate Injection, developed by Takeda. It is a selective bradykinin B2 receptor antagonist. It competitively blocks bradykinin-mediated vasodilation and vascular permeability elevation, rapidly relieving acute edema attacks of hereditary angioedema.
Main Indications
On-demand treatment of acute attacks of hereditary angioedema in adult patients with C1 esterase inhibitor deficiency.
Clinical Research
Global multicenter pivotal trials fully validated its rapid edema relief efficacy for hereditary angioedema patients;
Acute attack registration trials confirmed fast onset of symptom remission after subcutaneous single-dose administration;
Comparative efficacy studies showed reliable relief effect for cutaneous, abdominal and laryngeal edema episodes;
Tolerability observational research reflected transient local injection reactions as the main mild adverse event;
Long-term repeated administration follow-up trials verified no cumulative toxicity and controllable overall safety spectrum.
Common Side Effects
Common mild adverse reactions: Injection site erythema, swelling, pain, headache, dizziness and nausea;
Laboratory abnormalities: Rare transient mild liver enzyme fluctuation;
Severe but uncommon risks: Laryngeal edema aggravation, severe hypersensitivity reactions and anaphylaxis.
Approval Status in China
Firazyr® (specification 3ml:30mg per vial, 1 vial per box with 1 needle) obtained marketing approval in China in 2021. It is a subcutaneous injectable prescription orphan drug for rare disease treatment included in China’s Category B medical insurance catalogue.
Buy Firazyr (Icatibant Acetate Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
